Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지

Safety and Immunogenicity of Salmonella enterica Serovar Typhimurium llaB in Mice

  • CHO SUN-A (Department of Laboratory Animal Medicine, College of Veterinary Medicine and School of Agricultural Biotechnology, Seoul National University) ;
  • LEE IN-SOO (Department of Microbiology, Hannam University) ;
  • PARK JONG-HWAN (Department of Laboratory Animal Medicine, College of Veterinary Medicine and School of Agricultural Biotechnology, Seoul National University) ;
  • SEOK SEUNG-HYEOK (Department of Laboratory Animal Medicine, College of Veterinary Medicine and School of Agricultural Biotechnology, Seoul National University) ;
  • LEE HUI-YOUNG (Department of Laboratory Animal Medicine, College of Veterinary Medicine and School of Agricultural Biotechnology, Seoul National University) ;
  • KIM DONG-JAE (Department of Laboratory Animal Medicine, College of Veterinary Medicine and School of Agricultural Biotechnology, Seoul National University) ;
  • BACK MIN-WON (Department of Laboratory Animal Medicine, College of Veterinary Medicine and School of Agricultural Biotechnology, Seoul National University) ;
  • LEE SEOK-HO (Korean Food and Drug Administration) ;
  • HUR SOOK-JIN (Korean Food and Drug Administration) ;
  • BAN SANG-JA (Korean Food and Drug Administration) ;
  • LEE YOO-KYOUNG (Korean Food and Drug Administration) ;
  • PARK JAE-HAK (Department of Laboratory Animal Medicine, College of Veterinary Medicine and School of Agricultural Biotechnology, Seoul National University)
  • Published : 2005.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

The safety and immunogenicity of an attenuated recombinant Salmonella vaccine strain, Salmonella enterica serovar Typhimurium llaB, was assessed. This vaccine strain could survive in low pH condition, and its ability of intracellular survival did not differ from that of S. enterica serovar Typhimurium UK1, which is the wild-type of the vaccine strain. The mortality of the mice orally administered with the vaccine strain was $50\%$ at the dose of $10^7$ CFU. All mice administered with $10^5\;or\;10^3$ CFU of the vaccine strain survived for 3 days postinoculation (pi). However, all mice administered with more than $10^3$ CFU of the vaccine strain died within 3 days pi. To examine the protective effect of the vaccine strain, mice were orally immunized with $10^4\;and\;10^6$ CFU of the bacteria. Control mice were given with 0.5 ml of phosphate buffered saline (PBS). After 8 days, the mice were challenged with $10^9$ CFU of S. enterica serovar Typhimurium UK1, and mortality was examined for 5 days. The survival rates of the mice immunized with $10^4\;and\;10^6$ CFU of the vaccine strain were $60\%\;and\;80\%$, respectively, whereas all control mice died within 2 days after challenging. To investigate the immunogenicity of S. enterica serovar Typhimurium llaB, mice were orally immunized with $10^5\;or\;10^6$ CFU ml of the vaccine strain. Five mice of each group were sacrificed at 5 and 12 days after immunization, and results showed that immunization of the vaccine strain led to increases of IgG1, IgG2, and IgM titers against S. enterica serovar Typhimurium UK1 in mouse sera, cytokine expressions such as IL-2, IL-4, IL-6, and IL-10 in spleen, and the lymphocyte proliferation response to mitogens (concanavalin A or LPS) stimulation.

Keywords

References

  1. Charfield, S., M. Roberts., P. London, I. Cropley, G. Douce, and G. Dougan. 1993. The development of oral vaccines based on live attenuated Salmonella strain. FEMS Immunol. Med. Microbiol. 7: 1-7 https://doi.org/10.1111/j.1574-695X.1993.tb00374.x
  2. Cookson, B. T. and M. J. Bevan. 1997. Identification of a natural T cell epitope presented by Salmonella infected macrophages and recognized by T cells from orally immunized mice. J. Immunol. 158: 4310-4319
  3. Ferreccio, C., M. M. Levine, H. Rodriguez, and R. Contreras. 1989. Comparative efficacy of two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsule; a field trial in an endemic area Infect. Immun. 159: 766-769
  4. Foster, J. W. and B. Bearson. 1994. Acid-sensitive mutants of Salmonella typhimurium identification through a dinitrophenol lethal screening strategg. J. Bacteriol. 176: 2596-260 https://doi.org/10.1128/jb.176.9.2596-2602.1994
  5. Gill, H. S., D. L. Watson, and M. R. Brandon. 1992. In vivo inhibition by monoclonal antibody to CD4+ T cells of humoral and cellular immunity in sheep. Immunology 77: 38-42
  6. Hohmann, E. L., C. A. Oletta, K. P. Killeen, and S. I. Miller. 1996. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173: 1408-1414 https://doi.org/10.1093/infdis/173.6.1408
  7. Holly, E. A. and W. Foster. 1982. Bacteriophage P22 as a vector for Mu mutagenesis in Salmonella typhimurium: Isolation of nad-Iac and pnu-Iac gene fusion. J. Bacteriol. 152: 959-962
  8. Hone, D. M., C. O. Tacket, A. M. Harris, B. Kay, G. Losonsky, and M. M. Levine. 1992. Evaluation in volunteers of a candidate live oral attenuated S. typhi vector vaccine. J. Clin. Invest. 90: 412-420 https://doi.org/10.1172/JCI115876
  9. Ivanoff, B., M. M. Levine, and P. H. Lambert. 1994. Vaccination against typhoid fever: Present status. Bull. World Health Organ. 72: 957-971
  10. Jonson, V. J., M. Tsunoda, and R. P. Sharma. 2000. Increased production of proinflammatory cytokines by murine macrophage following oral exposure to sodium selenite but not to seleno-L-methionine. Arch. Environ. Contam. Toxicol. 39: 243-250 https://doi.org/10.1007/s002440010101
  11. Kim, S. H., O. Y. Lim, S. H. Kim, J. Y. Kim, Y. H. Kang, and B. K. Lee. 2003. Pulsed-field gel electrophoresis and mutation typing of gyrA gene of quinolone-resistant Salmonella enterica serovar paratyphi a isolated from outbreak and sporadic cases, 1998-2002, Korea. J. Microbiol. Biotechnol. 13: 155-158
  12. Lee, H. Y., J. H. Park, S. H. Seok, S. A. Cho, M. W. Baek, D. J. Kim, Y. H. Lee, and J. H. Park. 2004. Dietary intake of various lactic acid bacteria suppresses Type 2 helper T cell production in antigen-primed mice splenocyte. J. Microbiol. Biotechnol. 14: 167-170
  13. Levine, M. M., D. Herrington, J. R. Murphy, J. G. Morris, G. Losonsky, B. Tall, A. A. Lindberg, S. Svenson, S. Baqar, and M. F. Edwards. 1987. Safety, infectivity, immunogenicity and in vivo ability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccine in man. J. Clin. Invest. 79: 888-902 https://doi.org/10.1172/JCI112899
  14. Mosmann, T. R. and R. L. Coffman. 1989. Th1 and Th2 cells: Different patterns of Iymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7: 145-173 https://doi.org/10.1146/annurev.iy.07.040189.001045
  15. Muotiala, A. and P. H. Makela. 1990. The role of lNF-r in murine Salmonella typhimurium infection. Microb. Pathog. 8: 135-141 https://doi.org/10.1016/0882-4010(90)90077-4
  16. Pang, T., M. M. Levine, B. Ivanoff, J. Wain, and B. B. Finlay. 1998. Typhoid fever - important issues still remain. Trends Microbiol. 6: 131-133 https://doi.org/10.1016/S0966-842X(98)01236-0
  17. Raupach, B. S. and H. Kaufmann. 2001. Bacterial virulence, proinflammatory cytokines and host immunity: How to choose the appropriate Salmonella vaccine strain? Microbes Infect. 3: 1261-1269 https://doi.org/10.1016/S1286-4579(01)01486-1
  18. Sebastiani, G., V. Blais, V. Sancho, S. N. Vogel, M. M. Stevenson, P. Gros, J. M. Lapointe, S. Rivest, and D. Malo. 2002. Host immune response to Salmonella enterica serovar typhimurium infection in mice derived from wild strains. Infect. Immun. 70: 1997-2009 https://doi.org/10.1128/IAI.70.4.1997-2009.2002
  19. Sirard, J. C., F. Niedergang, and J. P. Kraehenbuhl. 1999. Live attenuated Salmonella: A paradigm of mucosal vaccines. Immunol. Rev. 171: 5-26 https://doi.org/10.1111/j.1600-065X.1999.tb01340.x
  20. Staats, H. F., R. J. Jackson, M. Marinaro, I. Takahashi, H. Kiyono, and J. R. McGhee. 1994. Mucosal immunity to infection with implication for vaccine development. Curr. Opin. Immunol. 6: 572-583 https://doi.org/10.1016/0952-7915(94)90144-9
  21. Tacket, C. O., D. M. Hone, R. I. Curtiss, S. M. Kelly, O. Losonsky, L. Guers, A. M. Harris, R. Edelman, and M. M. Levine. 1992. Comparison of the safety and immunogenicity of aroCaroD and cya,crp Salmonella typhi strains in adult volunteers. Infect. Immun. 60: 536-541
  22. Tacket, C. O., M. B. Sztein, S. S. Wasserman, G. Losonsky, K. L. Kotloff, T. L. Wyant, J. P. Nataro, R. Edelman, J. Perry, P. Bedford, D. Brown, S. Chatfield, G. Dougan, and M. M. Levine. 2000. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect. Immun. 68: 1196-1201 https://doi.org/10.1128/IAI.68.3.1196-1201.2000
  23. Thatte, J., S. Rath, and V. Bal. 1995. Analysis of immunization route-related variations in the immune response to heat-killed Salmonella typhimurium in mice. Infect. Immun. 63: 99-103
  24. Wang, J. Y., M. F. Pasetti, F. R. Noriega, R. I. Anderson, S. S. Wasserman, J. E. Galen, M. B. Sztein, and M. M. Levine. 2001. Construction, genotyping and phenotyping characterization, and immunogenicity of attenuated ${\Delta}$guaBA Salmonella enterica serovar typhi strain CDV 915. Infect. Immun. 69: 4734-4741 https://doi.org/10.1128/IAI.69.8.4734-4741.2001